《LANCET,3月11日,The value of early transmission dynamic studies in emerging infectious diseases》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-12
  • The value of early transmission dynamic studies in emerging infectious diseases

    Emma McBryde

    Open AccessPublished:March 11, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30161-4

    The world is braced for a public health emergency of international concern caused by a novel emerging infectious disease, a coronavirus with similarities to severe acute respiratory syndrome coronavirus (SARS-CoV). Person-to-person transmission of SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), started in December, 2019, in Wuhan, China and has spread to become a global pandemic, with, as of Feb 26, 2020, community transmission in Italy, Iran, and South Korea.

  • 原文来源:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30161-4/fulltext
相关报告
  • 《3月11日_早期传播动态研究在新发传染病中的价值》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-03-13
    • 3月11日_早期传播动态研究在新发传染病中的价值 1.时间:2020年3月11日 2.机构或团队:澳大利亚詹姆斯库克大学 3.事件概要: 澳大利亚詹姆斯库克大学的科研人员在The Lancet Infectious Diseases期刊在线发表题为“The value of early transmission dynamic studies in emerging infectious diseases”的评论性文章。 研究认为认为,建模研究从传染病的首次公布和致病病毒基因序列的发布开始,有助于对COVID-19动态的理解。对紧密相关病毒的初步系统发育分析表明,SARS-CoV-2在人与人之间的传播高度关联。文章指出,建模研究提供了简单的计算方法,确定了中国报告病例与来自旅行者的输入病例之间的不匹配。比如根据旅行量,建模研究人员推断武汉的病例被低估了40倍[1]。再次根据旅行量进行的进一步计算表明,预计一些国家的旅行相关病例将比已通报的多得多,提醒一些国家注意未发现病例和社区传播的可能性。传播动态模型是了解新兴传染病流行潜力的第一步,包括估计再生数。第一个发表的COVID-19传播动态研究迅速且不复杂,将基本再生数估计为随时间变化,而没有探索一些主要的基本假设,例如在潜伏期缺乏传染性。自该早期论文发表以来,出现了许多估计的繁殖率,范围从2到6。 Adam Kucharski及其同事的研究[2]提出了早期工作的许多假设。该报告提供了随时间变化的再生数,显示了中国从2020年1月23日起实施的大规模公共卫生干预措施的效果。通过利用与旅行相关的输出病例的其他数据集,Kucharski和同事们并不完全依赖于武汉市已通报的病例(这可能会因病例检测的时间变化而导致估算偏差)。Kucharski表明,在中国前所未有的公共卫生限制期间,再生数几乎降至阈值为1。Kucharski及其同事建议,传播链最初可能无法启动,可能需要多达4例输入病例才能建立传播。该估计假设SARS-CoV-2具有与SARS相似的异质性的传染性,SARS-CoV的特征是具有许多超级传播者,大多数病例没有感染其他人。如果SARS-CoV-2具有更同质的传染性特征(新出现的证据指向该特征),其中大多数人会感染另外两到三个人,则在单个输入病例中建立本地传播的风险要高的多。这项研究至少回答了关于这种新兴传染病的一个关键问题,即它的再生数。这个数量始于2.35,并且在2019年12月至2020年1月间下降到1.05。作者认为应该紧急解决一些问题,包括在病程中的传染性,尤其是那些无意识的人(包括无症状和轻度症状的人)可能发生多少传播。最初的报告表明,活病毒可以从无症状或轻度症状的人中恢复,这是引起人们极大关注的问题,因为它将使疾病更难以发现和控制。此外,必须确定感染的严重程度,包括不同年龄和风险人群的感染致命率。 研究人员认为中国大陆应继续进行建模和监测,以评估公共卫生措施的效果。但是,还必须将注意力转移到中国以外的新兴焦点,包括意大利、伊朗和韩国,以确定在不同的气候和社会背景下,繁殖率是否会有所不同。随着这种冠状病毒成为大流行,跨不同大陆的传染改变了对全球社区的风险。 4.附件: 原文链接:https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30161-4/fulltext [1] Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; (published online Jan 30.) DOI:10.1056/NEJMc2001468 [2]Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis. 2020 (published online March 11)
  • 《LANCET,3月20日,Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-21
    • Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases Kollengode Ramanathan, MD David Antognini, MBBS Alain Combes, MD Matthew Paden, MD Bishoy Zakhary, MD Mark Ogino, MD et al. Show all authors Show footnotes Published:March 20, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30121-1 Summary WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality.